Last update Nov. 6, 2022
Limited compatibility
We do not have alternatives for Pazopanib Hydrochloride.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Pazopanib Hydrochloride in other languages or writings:
Pazopanib Hydrochloride belongs to these groups or families:
Main tradenames from several countries containing Pazopanib Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 21 (14 - 39) | % |
Molecular weight | 474 | daltons |
Protein Binding | > 99 | % |
VD | 0.16 | l/Kg |
pKa | 10.41 | - |
Tmax | 2 - 4 | hours |
T½ | 31 - 35 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Inhibitor of BCR-ABL and SRC tyrosine kinase that is used for treatment of several neoplastic diseases (advanced renal cell carcinoma and advanced soft-tissue sarcoma). Oral administration once daily.
At latest update, relevant published data on excretion into breast milk were not found.
Its very high plasma protein binding makes it difficult its excretion into breast milk in significant amounts.
Its long half-life could facilitate excretion in breast milk and, although oral bioavailability is low, it doubles when ingested with food, so it could have a systemic action in infants.
The most common side effects of pazopanib are diarrhea and other gastrointestinal disorders. (Martindale)
It is known from pharmacokinetics that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½ it is 94%, after 5 T½, 96.9%, after 6 T½, 98.4% and after 7 T½ it is 99%. From 7 T½ the plasma concentrations of the drug in the body are negligible. In general, a period of at least five half-lives can be considered a safe waiting period before breastfeeding again.(Anderson 2016).
Taking the longest T½ published as a reference (35 hours), these 5 T½ would correspond to 175 hours (7 days). Meanwhile, express and discard milk from the breast regularly. This does not allow breastfeeding during treatment.
Abrupt weaning can be psychologically traumatic for both the mother and the infant. (Pistilli 2013).
Until more published data is known about this drug in relation to breastfeeding, better known alternatives may be preferable, especially during the neonatal period and in the event of prematurity.
If used during lactation, it is advisable to monitor growth and the possible appearance of diarrhea in the infant.
Given the strong evidence that exists regarding the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to evaluate the risk-benefit of any maternal treatment, including chemotherapy, individually advising each mother who wishes to continue with breastfeeding. (Koren 2013)
See below the information of this related product: